SAB Biotherapeutics Q1 Earnings Call Highlights SAB Biotherapeutics (
NASDAQ:SABS ) said its lead type 1 diabetes candidate, SAB-142, remains on track in a registrational Phase 2b trial, as the clinical-stage biopharmaceutical company reported a wider first-quarter loss alongside higher research and development spending.
Chief Executive Officer Sa
Why Is SAB BIO Stock Trading Lower On Tuesday? SAB BIO's SAB-142 Phase 1 trial data supports its safety and pharmacodynamic activity, paving the way for a Phase 2b trial in T1D in 2025.
Top movers in Friday's session Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Which stocks are gapping on Friday? The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Which stocks are moving before the opening bell on Wednesday? Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
SABS Stock Earnings: SAB Biotherapeutics Beats EPS for Q2 2024 SABS stock results show that SAB Biotherapeutics beat analyst estimates for earnings per share the second quarter of 2024.
